An update on oral cavity cancer: epidemiological trends, prevention strategies and novel approaches in diagnosis and prognosis.

Epidemiology Mouth Neoplasms Oral Cancer Risk Factors Squamous Cell Carcinoma Survival

Journal

Community dental health
ISSN: 0265-539X
Titre abrégé: Community Dent Health
Pays: England
ID NLM: 8411261

Informations de publication

Date de publication:
30 Aug 2022
Historique:
pubmed: 20 7 2022
medline: 9 9 2022
entrez: 19 7 2022
Statut: epublish

Résumé

In the UK, the incidence of oral cavity cancer continues to rise, with an increase of around 60% over the past 10 years. Many patients still present with advanced disease, often resulting in locoregional recurrence and poor outcomes, which has not changed significantly for over four decades. Changes in aetiology may also be emerging, given the decline of smoking in developed countries. Therefore, new methods to better target prevention, improve screening and detect recurrence are needed. High-throughput 'omics' technologies appear promising for future individual-level diagnosis and prognosis. However, given this is a relatively rare cancer with significant intra-tumour heterogeneity and variation in patient response, reliable biomarkers have been difficult to elucidate. From a public health perspective, implementing these novel technologies into current services would require substantial practical, financial and ethical considerations. This may be difficult to justify and implement at present, therefore focus remains on early detection using new patient-led follow-up strategies. This paper reviews the latest evidence on epidemiological trends in oral cavity cancer to help identify at risk groups, population-based approaches for prevention, in addition to potential cutting-edge approaches in the diagnosis and prognosis of this disease.

Identifiants

pubmed: 35852216
doi: 10.1922/CDH_00032Gormley09
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

197-205

Informations de copyright

Copyright© 2022 Dennis Barber Ltd.

Auteurs

M Gormley (M)

MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK.

E Gray (E)

University of Bristol Dental School, University Hospitals Bristol and Weston NHS Foundation Trust, UK.

C Richards (C)

Oral Surgery, School of Dentistry, Cardiff University, UK.

A Gormley (A)

University of Bristol Dental School, University Hospitals Bristol and Weston NHS Foundation Trust, UK.

R C Richmond (RC)

MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK.

E E Vincent (EE)

Translational Health Sciences, Bristol Medical School, University of Bristol, UK.

T Dudding (T)

University of Bristol Dental School, University Hospitals Bristol and Weston NHS Foundation Trust, UK.

A R Ness (AR)

NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, UK.

S J Thomas (SJ)

University of Bristol Dental School, University Hospitals Bristol and Weston NHS Foundation Trust, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH